

RANBAXY

PHARMACEUTICALS INC.

Phone: (609) 720-5622 • Fax (609) 514-9779

FAX

DATE: January 15, 2002

#OF PAGES: 12
(INCLUDING THIS COVER)

TO: Examiner S. Wright
FAX NO.: (703) 308-7922

FROM: Christine Kenedy, Legal Dept.


RE: 1-(4-ARYLPIPERAZIN-1-YL)- ω -[N-(α , ω -DICARBOXIMIDO)]-
ALKANES USEFUL AS UROSELECTIVE α 1-ADRENOCEPTOR
BLOCKERS
U.S. Serial No. 09/578,239
Filing Date: 5/24/2000
Attorney Ref. No.: RLL-5.4DIVUS

Dear Examiner Wright:

As you requested in your telephone message of earlier today, attached please find the Amendment and Response, as well as accompanying documents, mailed to the U.S. PTO on January 2, 2002.

Please let me know if you require any additional information.

Sincerely,



Christine Kenedy
Patent Legal Assistant
to Jayadeep R. Deshmukh

CONFIDENTIALITY NOTE:

The information contained in this facsimile message is strictly privileged and confidential, intended only for the use of the individual or entity named above.

If the reader of this message is not the intended recipient, or the employee or agent responsible to deliver it to the intended recipient, you are hereby notified that any dissemination, distribution or copying of this material is strictly prohibited.

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
RLL-5.4DIVUS

In Re Application Of: ANAND et al.

Serial No.
09/578,239

Filing Date
May 24, 2000

Examiner
S. Wright

Group Art Unit
1626

Title:

1-(4-ARYLPIPERAZIN-1-YL)-OMEGA-[N-(ALPHA,OMEGA-DICARBOXIMIDO)]-ALKANES USEFUL AS
UROSELECTIVE ALPHA1-ADRENOCEPTOR BLOCKERS

Address to:
Assistant Commissioner for Patents
Washington, D.C. 20231

37 CFR 1.97(b)

1. ☐ The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

37 CFR 1.97(c)

Adjustment date: 02/04/2002 AJOHNS01
017/15/2002 RHARNON 00000006 500912 09578239
01 FC:126 180.00 CH
The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:

☐ the statement specified in 37 CFR 1.97(e);

OR

☒ the fee set forth in 37 CFR 1.17(p).

01/15/2002 RHARNON 00000006 500912 09578239
01 FC:126 180.00 CH

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
RLL-5.4DIVUS

In Re Application: ANAND et al.

Serial No.

09/578,239

Filing Date

May 24, 2000

Examiner

S. Wright

Group Art Unit

1626

**1-(4-ARYLPIPERAZIN-1-YL)-OMEGA-[N-(ALPHA,OMEGA-DICARBOXIMIDO)]-ALKANES USEFUL AS
UROSELECTIVE ALPHA1-ADRENOCEPTOR BLOCKERS**

Payment of Fee

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- ☐ A check in the amount of _____ is attached.
- ☒ The Assistant Commissioner is hereby authorized to charge and credit Deposit Account No. 50-0912 as described below. A duplicate copy of this sheet is enclosed.
- ☒ Charge the amount of \$180.00
- ☒ Credit any overpayment.
- ☒ Charge any additional fee required.

Certificate of Transmission by Facsimile*

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (F

(Date)

Signature

Typed or Printed Name of Person Signing Certificate

Certificate of Mailing by First Class Mail

I certify that this document and fee is being deposited
January 2, 2002 with the U.S. Postal Service
as first class mail under 37 C.F.R. 1.8 and is
addressed to the Assistant Commissioner for Patents,
Washington, D.C. 20231.


Signature of Person Mailing Correspondence

Susan Dolci

Typed or Printed Name of Person Mailing Certificate

***This certificate may only be used if paying by
deposit account.**


Signature

Dated: January 2, 2002

Jayadeep R. Deshmukh
Reg. No. 34,507
Ranbaxy Pharmaceuticals Inc.
Suite 2100
600 College Road East
Princeton, NJ 08540
Telephone: (609) 720-5608
Facsimile: (609) 514-9779

CC: